Uncategorized
Glaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass System
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking authorization to study its iStent infinite™ Trabecular Micro-Bypass System. The iStent infinite is d